Vivimusta Patent Expiration

Vivimusta is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 29, 2042. Details of Vivimusta's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844784 Stable pharmaceutical compositions of bendamustine
Jul, 2042

(17 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vivimusta's patents.

Given below is the list of recent legal activities going on the following patents of Vivimusta.

Activity Date Patent Number
Patent litigations
Email Notification 20 Dec, 2023 US11844784
Recordation of Patent Grant Mailed 19 Dec, 2023 US11844784
Recordation of Patent eGrant 19 Dec, 2023 US11844784
Patent Issue Date Used in PTA Calculation 19 Dec, 2023 US11844784
Patent eGrant Notification 19 Dec, 2023 US11844784
Mail Patent eGrant Notification 19 Dec, 2023 US11844784
Email Notification 30 Nov, 2023 US11844784
Issue Notification Mailed 29 Nov, 2023 US11844784
Application Is Considered Ready for Issue 13 Nov, 2023 US11844784
Dispatch to FDC 13 Nov, 2023 US11844784

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Vivimusta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vivimusta's family patents as well as insights into ongoing legal events on those patents.

Vivimusta's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Vivimusta's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 29, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Vivimusta Generics:

Bendamustine Hydrochloride is the generic name for the brand Vivimusta. 11 different companies have already filed for the generic of Vivimusta, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vivimusta's generic

Alternative Brands for Vivimusta

There are several other brand drugs using the same active ingredient (Bendamustine Hydrochloride) as Vivimusta. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Cephalon
Treanda
Eagle Pharms
Belrapzo
Bendeka


Apart from brand drugs containing the same ingredient, some generics have also been filed for Bendamustine Hydrochloride, Vivimusta's active ingredient. Check the complete list of approved generic manufacturers for Vivimusta





About Vivimusta

Vivimusta is a drug owned by Azurity Pharmaceuticals Inc. Vivimusta uses Bendamustine Hydrochloride as an active ingredient. Vivimusta was launched by Azurity in 2022.

Approval Date:

Vivimusta was approved by FDA for market use on 07 December, 2022.

Active Ingredient:

Vivimusta uses Bendamustine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Bendamustine Hydrochloride ingredient

Dosage:

Vivimusta is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
100MG/4ML (25MG/ML) SOLUTION Prescription INTRAVENOUS